トップページ

Novartis 

 

2006/12/14 Nestle

Nestle to Acquire Novartis Medical Nutrition, Moving Toward Nutrition, Health and Wellness

As a part of its continuing efforts to reinforce the Group's leading position in nutrition, Nestle has agreed to acquire the entire medical nutrition business of Novartis for a total amount of USD 2.5 billion. The move propels Nestle into a strong number two position in the fast growing and profitable healthcare nutrition segment, where so far Nestle played only a minor role. Through this acquisition Nestle also strengthens its existing R&D capability, helping to accelerate the growth of the nutrition business.


日本経済新聞 2006/12/15

医療用食品でネスレは世界5位でノバルティスは2位。今回の買収でネスレのシェアは25%となり、最大手でシェア30%の米アボット・ラボラトリーズに次ぐ2位に浮上する。

 


April 07, 2008 Novartis

Novartis to further strengthen its healthcare portfolio by acquiring 25% stake in Alcon from Nestlé with right to take over majority ownership of the world leader in eye care

アルコンは1945年に米テキサス州で薬局として創業し、点眼薬やコンタクトレンズケア商品など眼科分野の最大手メーカー。78年にネスレが買収し、77%の株式を保有する。

  その後

  ノバルティス、アルコン株の77%を取得 http://www.novartis.co.jp/news/2010/pr20100831.html

  ノバルティス株主総会、アルコン統合を承認 http://www.novartis.co.jp/news/2011/pr20110411.html

 


Nov 3, 2009 Reuters

Novartis invests $1 bln in China R&D plant

* Emphasises importance of emerging markets
* Invests further $250 mln in second plant

Swiss drugmaker Novartis AG is investing $1 billion to build the largest pharmaceutical research plant in China, emphasising the importance of developing markets for future growth.

Novartis and other drugmakers are keen to tap into markets such as China as they face slowing growth and loss of exclusivity on key products, including the Swiss group's top-selling blood pressure medicine Diovan. Novartis said it was also investing $250 million in a second research and development and manufacturing facility in Changshu
江蘇省常熟市.

The Switzerland-based drug maker launched an integrated biomedical R&D center in Shanghai's Zhangjiang Hi-Tech Park 張江ハイテクパーク two years ago and has already invested US$100 million in the center. The primary research at the center covers cancer as well as innovative chemistry and biomarket.

The company aims to deepen cooperation with Shanghai and build the R&D center into China's largest integrated bio-pharmaceutical R&D center by next year, said the English-language news paper.

Novartis has teamed up with the Institute of Biomedical Science of Fudan University
復旦大学 for cancer research in 2008.

Novatis' China sales jumped 29% from a year ago to RMB 3.3 billion last year, accounting for nearly 8% of its global sales.


November 11, 2013 Novartis

Novartis announces divestiture of its blood transfusion diagnostics unit to Grifols

Novartis announced a definitive agreement to divest its blood transfusion diagnostics unit to Grifols for USD 1.675 billion. This transaction, requiring customary regulatory approvals, is expected to be completed in the first half of 2014.

"The sale of the Novartis blood transfusion diagnostics unit enables us to focus more sharply on our strategic businesses while providing Grifols with a platform for global expansion," said Joseph Jimenez CEO of Novartis. "I am especially pleased that the agreement with Grifols provides our associates with an opportunity to join a company that will focus on growing this business aggressively."

Acquired in 2006 as part of Chiron, the blood transfusion diagnostics unit has formed part of Novartis Vaccines and Diagnostics. The blood transfusion diagnostics unit is dedicated to increasing transfusion safety worldwide with nucleic acid testing, blood testing products and immunoassay reagents that detect infectious disease. Headquartered in Emeryville, California, its net sales in 2012 were approximately USD 565 million. Not included in the sale is the Novartis companion diagnostics unit that is integrated into the pharmaceuticals business, nor the Genoptix business, as these are closely linked to the pharmaceuticals pipeline.

Headquartered in Barcelona, Spain, Grifols is the world's third largest producer of plasma-derived therapies.

Grifols is a global healthcare company whose mission is to improve the health and well being of people around the world. We accomplish this mission by producing life-saving protein therapies for patients and by providing hospitals, pharmacies and healthcare professionals with the tools they need to deliver expert medical care.

We have three primary divisions -- Bioscience, Diagnostic and Hospital – which develop, produce and market our innovative products and services to medical professionals in more than 90 countries around the world.

-----------

As of 2006, Chiron, Corp. was acquired by Novartis.
Chiron operates as a biopharmaceutical company in blood testing, vaccines, and biopharmaceuticals segments. The Blood Testing segment develops and sells nucleic acid testing (NAT) products to screen blood, plasma, organs, and tissue for viral infection. It has an alliance with Gen-Probe Incorporated for NAT products. This segment also provides immunodiagnostic tests to detect retroviruses and hepatitis viruses in blood in collaboration with Ortho-Clinical Diagnostics, Inc.

 


April 22, 2014  Novartis

Novartis announces portfolio transformation, focusing company on leading businesses with innovation power and global scale: Pharmaceuticals, Eye Care and Generics

Transactions improve Novartis' financial strength going forward

Basel, April 22, 2014 - Novartis announced today that it has reached a definitive agreement with GlaxoSmithKline plc (GSK) to exchange certain assets, building global leadership in key segments and focusing the company's portfolio. Under the agreement, Novartis would strengthen the company's innovative pharmaceuticals business by acquiring GSK oncology products, and would divest Vaccines (excluding flu) to them. The two companies would also create a joint venture, combining their consumer divisions to create a world-leading consumer healthcare business. Separately, the company announced a definitive agreement with Eli Lilly and Company (Lilly) to divest the Animal Health Division, further focusing its portfolio on the leading businesses of innovative pharmaceuticals, eye care and generics.

"The transactions mark a transformational moment for Novartis. They focus the company on leading businesses with innovation power and global scale. They also improve our financial strength, and are expected to add to our growth rates and margins immediately," said Joseph Jimenez, CEO of Novartis. "We have also created a world-leading consumer healthcare business in our joint venture with GSK. We believe the divestment of our smaller Vaccines and Animal Health Divisions will enable us to realize immediate value from these businesses for our shareholders, and those divisions will benefit from being part of large, global businesses that are also leaders in their segments. Patients will benefit from even higher levels of innovation that this focus may afford. Looking ahead, this positions Novartis well for future healthcare industry dynamics."

Deal terms and financials

Acquisition of GSK oncology products
Novartis has agreed to acquire GSK oncology products for a USD 14.5 billion payment and up to USD 1.5 billion contingent on a development milestone. Under the terms of the transaction, Novartis would have opt-in rights to GSK's current and future oncology R&D pipeline.

Divestment of Vaccines to GSK
Novartis has agreed to divest its Vaccines business to GSK, currently excluding its flu business, for USD 7.1 billion plus royalties. The USD 7.1 billion consists of USD 5.25 billion upfront and up to USD 1.8 billion in milestones. As a part of a value-maximization strategy in the context of the portfolio review, Novartis has initiated a separate sales process for its flu business.

Combination of Novartis OTC with GSK Consumer Healthcare in a joint venture
Novartis and GSK have agreed to create a world-leading consumer healthcare business through a joint venture between Novartis OTC and GSK Consumer Healthcare. Upon completion, Novartis will own a 36.5% share of the joint venture and will have four of eleven seats on the joint venture's Board. Furthermore, Novartis will have customary minority rights and exit rights at a pre-defined, market-based pricing mechanism.

Divestment of Animal Health Division to Lilly
In a separate transaction, Novartis has agreed to divest its Animal Health Division to Lilly for approximately USD 5.4 billion. This transaction is the result of a competitive process, which upon completion would create a leading animal health business under Lilly's ownership and would optimize the value of the asset in the interest of Novartis shareholders.

The overall financing for Novartis' obligations in the transactions is planned to be provided through a combination of excess liquidity at the time of closing, short-term financing instruments and limited new bond issues if needed.

Novartis continues to be committed to a double-A credit rating.

The elements of the transaction with GSK are inter-conditional and subject to approval by GSK shareholders. All transactions are subject to closing conditions, including anti-trust approvals. The Novartis Board unanimously believes that the transactions with GSK and the transaction with Lilly are in the best interests of Novartis and the Novartis Shareholders as a whole. The transaction with Lilly is expected to close by the end of the first quarter of 2015 and the transaction with GSK is expected to close during the first half of 2015.

Substantial exceptional gains are expected for the divested businesses at the time when the respective transactions close. Further details on the discontinuing operations classification will be provided during the second quarter of 2014.

2013 actual net sales results of Novartis' Vaccines (including flu) were approximately USD 1.4 billion[2]. Net sales of OTC were USD 2.9 billion and Animal Health were USD 1.1 billion.

Building leading businesses with enhanced innovation for patients

Novartis' acquisition of GSK oncology products is expected to further reinforce its leading Oncology business and improve the growth profile of the combined portfolio. Novartis has one of the industry's largest and most robust oncology pipelines, with more than 25 new molecular entities targeting key oncogenic pathways and 24 pivotal trials underway exploring 16 new products and indications. The addition of the GSK products is expected to expand Novartis' position in targeted therapies and small molecules.

Based on the depth and breadth of Novartis' R&D capabilities, it is anticipated that Novartis will be able to optimize these compounds. In particular, Novartis' scale in oncology development and commercial capabilities would additionally create the potential to optimize the launch of these two recently approved products for metastatic melanoma, Tafinlar®, a B-RAF inhibitor, and Mekinist(TM), a MEK inhibitor, positioning Novartis as the leader in treating melanoma. Votrient®, a VEGFR inhibitor for renal cell carcinoma, is also expected to reach more patients in our hands. Votrient has shown significant efficacy as first-line treatment for renal cancer, and also has potential for the adjuvant setting. Additional products included in the transaction include Tykerb® for HER2+ metastatic breast cancer, Arzerra® in chronic lymphocytic leukemia, and Promacta® for thrombocytopenia. Novartis will have opt-in rights for GSK's current and future oncology R&D pipeline, which could be a source of new compounds and new targets. Sales of the acquired GSK oncology products in 2013 were approximately USD 1.6 billion[3].

The joint venture of Novartis OTC and GSK Consumer Healthcare would establish a global consumer healthcare leader with approximately USD 10 billion in annual sales, and leading positions in four key OTC categories - Wellness, Oral Health, Nutrition and Skin Health. The joint venture would have several strong brands with almost half of the sales derived from brands larger than USD 300 million in annual revenue. The geographic footprint would span all regions, with scale and commercial presence in the developed world as well as in key emerging markets, such as Brazil, China, Mexico and Russia.

Novartis Vaccines would become part of a world leader in the vaccines segment, under GSK's ownership. The combined business is expected to have a compelling position in pediatric and meningitis franchises. GSK's position in the market is further likely to strengthen the commercial launch power behind Bexsero®. In addition, GSK has the capacity to fully fund the vaccines pipeline to potentially expand the R&D efforts of the rich vaccines pipeline portfolio.

Delivers compelling value for shareholders

The acquisition of GSK oncology products is projected to drive top-line growth and creates value by leveraging Novartis' strong development and commercial capabilities, as well as providing access to additional innovative therapies.

The formation of a world-leading consumer healthcare business with GSK allows us a significant share of the value created in this attractive business segment due to scale, complementary product portfolio and geographic footprint. Novartis' share of the joint venture would reflect the full value of Novartis' OTC Division.

The terms of the divestment of the Vaccines business would maximize the value of its pipeline, including Bexsero.

The divestment of Animal Health would recognize the full value of the business.

The transactions are expected to improve Novartis' sales and core operating income growth rates, while improving margins[1]. Each of the transactions is projected to be value creating.

These transactions represent a transformation for Novartis. We have leading positions in our core businesses in high-growth segments of healthcare. This will enable us to continue to build the world's most respected and successful healthcare company. Our strategic focus on science-based innovation and our global scale position the company well to meet the changes in the healthcare industry for the coming decade and beyond.


2016/11/22

Novartis、米Selexys Pharmaceuticalsを買収

欧州2位の製薬会社、スイスのNovartis AGは同業の米Selexys Pharmaceuticals Corp.を最大665百万ドルで買収した。Selexys が開発を進める遺伝性血液疾患の治療薬を得るため、2012年に合意していた買収実施の権利を行使した。

Selexys が試験薬「SelG1」が鎌状赤血球病(sickle cell disease)の合併症を抱える患者への治療に有効であることを示す有望な試験データを公表したのを受け、買収実行を決めた。